chronic transfusions and/or splenectomy at early development or during physiological stress or serious infections. Most affected individuals who are asymptomatic, paradoxically due to enhanced oxygen-transfer capacity, do not require any treatment. However, for some of the most severe cases, while extremely rare population-wise with estimated prevalence of 51 per million (Beutler, E. *Blood* **2000,** *95* (11), 3585-8), there is no disease-modifying treatment available for these patients other than palliative care (Tavazzi, D. et al., *Pediatr Ann* **2008,** *37* (5), 303-10). These hereditary non-spherocytic hemolytic anemia (HNSHA) patients present a clear unmet medical need.

Heterogenous genetic mutations in PKR lead to dysregulation of its catalytic activity. Since the initial cloning of PKR and report of a single point mutation Thr^{384}>Met associated with a HNSHA patient (Kanno, H. et al., *Proc Natl Acad Sci U S A* **1991,** *88* (18), 8218-21), there are now nearly 200 different reported mutations associated with this disease reported worldwide (Zanella, A. et al., *Br J Haematol* **2005,** *130* (1), 11-25; Kedar, P., et al., *Clin Genet* **2009,** *75* (2), 157-62; Fermo, E. et al., *Br J Haematol* **2005,** *129* (6), 839-46; Pissard, S. et al., *Br J Haematol* **2006,** *133* (6), 683-9). Although these mutations represent wide range genetic lesions that include deletional and transcriptional or translational abnormalities, by far the most common type is missense mutation in the coding region that one way or another affects conserved residues within domains that are structurally important for optimal catalytic function of PKR. The pattern of mutation prevalence seems to be unevenly distributed toward specific ethnic backgrounds. For instance, the most frequent codon substitutions reported for North American and European patients appear to be Arg^{486}>Trp and Arg^{510}>Gln, while mutations Arg^{479}>His, Arg^{490}>Trp and Asp^{331}>Gly were more frequently found in Asian patients (Kedar, P., et al., *Clin Genet* **2009,** *75* (2), 157-62).

SUMMARY

The present disclosure provides a method for increasing lifetime of the red blood cells (RBCs) in need thereof comprising contacting blood with an effective amount of (1) a compound disclosed herein or a pharmaceutically acceptable salt thereof; (2) a composition comprising a compound disclosed herein or a salt thereof and a carrier; or (3) a pharmaceutical composition comprising a compound disclosed

herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present disclosure further provides a method for regulating 2,3-diphosphoglycerate levels in blood in need thereof comprising contacting blood with an effective amount of (1) a compound disclosed herein or a pharmaceutically acceptable salt thereof; (2) a composition comprising a compound disclosed herein or a salt thereof and a carrier; or (3) a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present disclosure also provides a method for treating hereditary non-spherocytic hemolytic anemia comprising administering to a subject in need thereof a therapeutically effective amount of (1) a compound disclosed herein or a pharmaceutically acceptable salt thereof; (2) a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present disclosure further provides a method for treating sickle cell anemia comprising administering to a subject in need thereof a therapeutically effective amount of (1) a compound disclosed herein or a pharmaceutically acceptable salt thereof; (2) a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present disclosure further provides a method for treating hemolytic anemia (e.g., chronic hemolytic anemia caused by phosphoglycerate kinase deficiency, Blood Cells Mol Dis, 2011; 46(3):206) comprising administering to a subject in need thereof a therapeutically effective amount of (1) a compound disclosed herein or a pharmaceutically acceptable salt thereof; (2) a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


The present disclosure further provides a method for treating thalassemia (e.g., beta-thalassemia), hereditary spherocytosis, hereditary elliptocytosis, abetalipoproteinemia (or Bassen-Kornzweig syndrome), paroxysmal nocturnal hemoglobinuria, acquired hemolytic anemia (e.g., congenital anemias (e.g.,

enzymopathies)), or anemia of chronic diseases comprising administering to a subject in need thereof a therapeutically effective amount of (1) a compound disclosed herein or a pharmaceutically acceptable salt thereof; (2) a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present disclosure further provides a method for treating diseases or conditions that are associated with increased 2,3-diphosphoglycerate levels (e.g., liver diseases (Am J Gastroenterol, 1987;82(12):1283) and Parkinson's (J. Neurol, Neurosurg, and Psychiatry 1976,39:952) comprising administering to a subject in need thereof a therapeutically effective amount of (1) a compound disclosed herein or a pharmaceutically acceptable salt thereof; (2) a pharmaceutical composition comprising a compound disclosed herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Compounds and compositions described herein are activators of PKR mutants having lower activities compared to the wild type, thus are useful for methods of the present disclosure. Such mutations in PKR can affect enzyme activity (catalytic efficiency), regulatory properties (modulation by fructose bisphosphate (FBP)/ATP), and/or thermostability of the emzyme. Examples of such mutations are described in Valentini et al, JBC 2002. Some examples of the mutants that are activated by the compounds described herein include G332S, G364D, T384M, G37E, R479H, R479K, R486W, R532W, R510Q, and R490W. Without being bound by theory, compounds described herein affect the activities of PKR mutants by activating FBP non-responsive PKR mutants, restoring thermostability to mutants with decreased stability, or restoring catalytic efficiency to impaired mutants. The activating activity of the present compounds against PKR mutants may be tested following a method described in Example 1. Compounds described herein are also activators of wild type PKR.

In one aspect, the present disclosure refers to use of a compound of Formula I or a pharmaceutically acceptable salt thereof in preparation of a medicament for activating mutant PKR in red blood cells, wherein Formula I is represented by



(I)

wherein

W, X, Y and Z are each independently CH or N;

D and D^1 are independently a bond or NR^b;

A is optionally substituted aryl or optionally substituted heteroaryl;

L is a bond, -C(O)-, $-(CR^cR^c)_m$-, -OC(O)-, $-(CR^cR^c)_m$-OC(O)-, $-(CR^cR^c)_m$-C(O)-, $-NR^bC(S)$-, or $-NR^bC(O)$-, wherein the point of the attachment to R^1 is on the left-hand side;

R^1 is alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; each of which is substituted with 0-5 occurrences of R^d;

each R^3 is independently halo, haloalkyl, alkyl, hydroxyl or $-OR^a$, or two adjacent R^3 taken together with the carbon atoms to which they are attached form an optionally substituted cyclyl;

each R^a is independently alkyl, acyl, hydroxyalkyl or haloalkyl;

each R^b is independently hydrogen or alkyl;

each R^c is independently hydrogen, halo, alkyl, alkoxy or halo alkoxy or two R^c taken together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl;

each R^d is independently halo, haloalkyl, haloalkoxy, alkyl, alkynyl, nitro, cyano, hydroxyl, $-C(O)R^a$, $-OC(O)R^a$, $-C(O)OR^a$, $-SR^a$, $-NR^aR^b$ or $-OR^a$, or two R^d taken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl;

n is 0, 1, or 2;

m is 1, 2 or 3;

h is 0, 1 or 2; and


g is 0, 1 or 2.

In another aspect, the present disclosure refers to use of a compound of Formula I or a pharmaceutically acceptable salt thereof in preparation of a medicament for activating wild-type PKR in red blood cells, wherein Formula I is as defined above.

In an example, to increase the lifetime of the red blood cells, a compound, composition or pharmaceutical composition described herein is added directly to whole blood or packed cells extracorporeally or be provided to the subject (e.g., the patient) directly (e.g., by i.p., i.v., i.m., oral, inhalation (aerosolized delivery),

transdermal, sublingual and other delivery routes). Without being bound by theory, compounds described herein increase the lifetime of the RBCs, thus counteract aging of stored blood, by impacting the rate of release of 2,3-DPG from the blood. A decrease in the level of 2, 3-DPG concentration induces a leftward shift of the oxygen-hemoglobin dissociation curve and shifts the allosteric equilibribrium to the R, or oxygenated state, thus producing a therapeutic inhibition of the intracellular polymerization that underlies sickling by increasing oxygen affinity due to the 2,3-DPG depletion, thereby stabilizing the more soluble oxy-hemoglobin. Accordingly, in one example, compounds and pharmaceutical compositions described herein are useful as antisickling agents. In another example, to regulate 2,3-diphosphoglycerate, a compound, composition or pharmaceutical composition described herein is added directly to whole blood or packed cells extracorporeally or be provided to the subject (e.g., the patient) directly (e.g., by i.p., i.v., i.m., oral, inhalation (aerosolized delivery), transdermal, sublingual and other delivery routes).

In one example, provided is a pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt of formula (I):



(I)

wherein:

W, X, Y and Z are each independently selected from CH or N;

D and D^1 are independently selected from a bond or NR^b;

A is optionally substituted aryl or optionally substituted heteroaryl;

L is a bond, -C(O)-, $-(CR^cR^c)_m-$, -OC(O)-, $-(CR^cR^c)_m$-OC(O)-, $-(CR^cR^c)_m$-C(O)-, $-NR^bC(S)-$, or $-NR^bC(O)-$ (wherein the point of the attachment to R^1 is on the left-hand side);


R^1 is selected from alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl; each of which is substituted with 0-5 occurrences of R^d;

each R^3 is independently selected from halo, haloalkyl, alkyl, hydroxyl and $-OR^a$, or two adjacent R^3 taken together with the carbon atoms to which they are

CLAIMS

What is claimed is:

1. Use of a compound of Formula I or a pharmaceutically acceptable salt thereof in preparation of a medicament for activating mutant PKR in red blood cells, wherein Formula I is represented by



(I)

wherein

W, X, Y and Z are each independently CH or N;

D and D^1 are independently a bond or NR^b;

A is optionally substituted aryl or optionally substituted heteroaryl;

L is a bond, -C(O)-, $-(CR^cR^c)_m$-, -OC(O)-, $-(CR^cR^c)_m$-OC(O)-, $-(CR^cR^c)_m$-C(O)-, $-NR^bC(S)$-, or $-NR^bC(O)$-, wherein the point of the attachment to R^1 is on the left-hand side;

R^1 is alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl; each of which is substituted with 0-5 occurrences of R^d;

each R^3 is independently halo, haloalkyl, alkyl, hydroxyl or $-OR^a$, or two adjacent R^3 taken together with the carbon atoms to which they are attached form an optionally substituted cyclyl;

each R^a is independently alkyl, acyl, hydroxyalkyl or haloalkyl;

each R^b is independently hydrogen or alkyl;

each R^c is independently hydrogen, halo, alkyl, alkoxy or halo alkoxy or two R^c taken together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl;

each R^d is independently halo, haloalkyl, haloalkoxy, alkyl, alkynyl, nitro, cyano, hydroxyl, $-C(O)R^a$, $-OC(O)R^a$, $-C(O)OR^a$, $-SR^a$, $-NR^aR^b$ or $–OR^a$, or two R^d taken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl;

n is 0, 1, or 2;


m is 1, 2 or 3;

h is 0, 1 or 2; and

g is 0, 1 or 2.

2. Use of a compound of Formula I or a pharmaceutically acceptable salt thereof in preparation of a medicament for activating wild-type PKR in red blood cells, wherein Formula I is as defined in claim 1.

3. The use of claim 1 or 2, wherein the compound is represented by formula (I):



(I)

wherein:

W, X, Y and Z are each independently CH or N;

D and D^1 are independently a bond or NR^b;

A is optionally substituted bicyclic heteroaryl;

L is a bond, -C(O)-, $-(CR^cR^c)_m$-, -OC(O)-, $-(CR^cR^c)_m$-OC(O)-, $-(CR^cR^c)_m$-C(O)-, $-NR^bC(S)$-, or $-NR^bC(O)$- (wherein the point of the attachment to R^1 is on the left-hand side);

R^1 is alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; each of which is substituted with 0-5 occurrences of R^d;

each R^3 is independently halo, haloalkyl, alkyl, hydroxyl or $-OR^a$; or two adjacent R^3 taken together with the carbon atoms to which they are attached form an optionally substituted cyclyl;

each R^a is independently alkyl, acyl, hydroxyalkyl or haloalkyl;

each R^b is independently hydrogen or alkyl;

each R^c is independently hydrogen, halo, alkyl, alkoxy or halo alkoxy or two R^c taken together with the carbon atoms to which they are attached form an optionally substituted cycloalkyl;

each R^d is independently halo, haloalkyl, haloalkoxy, alkyl, alkynyl, nitro, cyano, hydroxyl, $-C(O)R^a$, $-OC(O)R^a$, $-C(O)OR^a$, $-SR^a$, $-NR^aR^b$ or $–OR^a$, or two R^d taken together with the carbon atoms to which they are attached form an optionally substituted heterocyclyl;

n is 0, 1, or 2;

m is 1, 2 or 3;

h is 0, 1 or 2; and

g is 0, 1 or 2.

4. The use of any one of claims 1-3, wherein h is 1 and g is 1.

5. The use of claim 4, wherein W, X, Y and Z are CH.

6. The use of claim 5, wherein D is NR^b and D^1 is a bond.

7. The use of claim 6, wherein R^b is H, methyl or ethyl.

8. The use of claim 7, wherein L is a bond, $-(CR^cR^c)_m-$, $-NR^bC(O)-$,$-(CR^cR^c)_m-C(O)-$, -C(O)-, or -O(CO)-.

9. The use of claim 8, wherein L is a bond and R^1 is alkyl, aryl or heteroaryl substituted with 0-5 occurrences of R^d.

10. The use of claim 8, wherein L is $-(CR^cR^c)_m-$ and R^1 is cycloalkyl, aryl, heteroaryl or heterocyclyl substituted with 0-5 occurrences of R^d.

11. The use of claim 8, wherein L is $-NR^bC(O)-$ and R^b is hydrogen and R^1 is aryl substituted with 0-5 occurrences of R^d.

12. The use of claim 8, wherein L is $-(CR^cR^c)_m-C(O)-$ and R^1 is cycloalkyl, aryl or heteroaryl substituted with 0-5 occurrences of R^d.

13. The use of claim 8, wherein L is -C(O)- and R^1 is aryl, alkyl, or heteroaryl substituted with 0-5 occurrences of R^d.


14. The use of claim 8, wherein L is $-OC(O)-$ and R^1 is alkyl, aryl or heterocyclyl substituted with 0-5 occurrences of R^d.

15. The use of claim 8, wherein L is $-(CR^cR^c)_mC(O)-$ and R^1 is heterocyclyl or cycloalkyl substituted with 0-5 occurrences of R^d.

16. The use of any one of claims 1 to 15, wherein n is 0.


17. The use of any one of claims 1 to 15, wherein n is 1 and R^3 is CH_3, CH_2CH_3, OCH_3, OCH_2CH_3, OH, F, Cl, or CF_3.

18. The use of any one of claims 1 to 15, wherein the compound is represented by formula (Id):

















(Id).











19. The use of any one of claims 1 to 18, wherein A is optionally substituted quinolinyl.













20. The use of any one of claims 1 to 19, wherein A is .











21. The use of claim 1 or 2, wherein the compound is selected from the group consisting of:











	
	











	
	
	
	
	













	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	













	
	
	
	
	













	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	











	
	
	
	
	
	













	
	
	
	
	
	











	
	
	
	
	
	











	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	












	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	 Chiral













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	Chiral 
Chiral 	
Chiral 	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	
	
	Chiral 
	













	
	
	
	
	
	













	
	
	
	
	
	













	
	
	 Chiral
	
	
	













	
	
	
	
	
	













	
	
	
	
	
	


	
	
	
	
	
	


	 Chiral
 Chiral	
	
	
	
	


	
	
	
	
	
	


	
	
	
	
	
	


	
	
	
	
	
	








































and



 .	



22. The use of claim 1 or 2, wherein the compound is selected from a group consisting of:



, ,



, , ,









, ,

, ,


, ,

, ,


, ,


,

,

,

,

,

,

, and

.

23. The use of claim 1 or 2, wherein the compound is:


.

24. The use of claim 1 or 2, wherein the compound is:


.